title: Intrauterine PGF2 alpha infusion for termination of pregnancies with second-trimester rupture of membranes.
abstract: Intrauterine prostaglandin (PG) F2 alpha infusion and intravenous (IV) oxytocin infusion were compared to evaluate the effectiveness of the two methods for termination of pregnancies with second-trimester rupture of membranes. Twenty-two women with this complication were randomly allocated to receive either 20 mg PGF2 alpha, diluted in 500 mL of NaCl 0.9% and administered through a Foley catheter inserted through the cervix, or IV oxytocin infusion in increasing doses. All subjects in the PGF2 alpha group aborted after the first administration. Repeat infusion was necessary in three oxytocin-treated subjects. The mean (+/- SD) induction-abortion interval was significantly shorter in those receiving PGF2 alpha (6.7 +/- 1.2 hours) than in those receiving oxytocin (8.8 +/- 2.7 hours). Minor side effects, such as nausea and vomiting, were observed in three women during PGF2 alpha infusion and were treated symptomatically and by temporary interruption of the infusion. Uterine hypertonus, observed in one subject in each group, was treated by temporary cessation of the infusion. We conclude that intrauterine PGF2 alpha infusion seems more effective than IV oxytocin for termination of pregnancies with second-trimester rupture of membranes.
authors.affiliation: Department of Obstetrics and Gynecology, Hillel Jaffe Medical Center, Hadera, Israel.
authors.forename: O E
authors.initials: OE
authors.lastname: Jaschevatzky
authors.forename: S
authors.initials: S
authors.lastname: Dascalu
authors.forename: Y
authors.initials: Y
authors.lastname: Noy
authors.forename: R P
authors.initials: RP
authors.lastname: Rosenberg
authors.forename: S
authors.initials: S
authors.lastname: Anderman
authors.forename: S
authors.initials: S
authors.lastname: Ballas
mesh_terms: D000032:Abortion, Therapeutic / Q000379:methods*; D015237:Dinoprost / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005322:Premature Rupture of Fetal Membranes; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral / Q000379:methods; D010121:Oxytocin / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011897:Random Allocation; D014599:Uterus
chemical_list: D010121:Oxytocin; D015237:Dinoprost